Stefan W Krause
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Behringer K, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause S, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, Bentz M, Vieler T, Kriz J, Goergen H, Tanner A, Zijlstra J, Greil R, Markova J, Sasse S, Fuchs M, Topp M, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann H, Schalk E, Semrau R. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2014; 385:1418-27.
Dec 22, 2014Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Dec 22, 2014Lancet 2014; 385:1418-27
Behringer Karolin, Lange Elisabeth, Mahlberg Rolf, Hassler Andre, Vogelhuber Martin, Hahn Dennis, Mezger Jörg, Krause Stefan W, Skoetz Nicole, Böll Boris, von Tresckow Bastian, Diehl Volker, Hallek Michael, Borchmann Peter, Stein Harald, Eich Hans, Engert Andreas, Bentz Martin, Vieler Tom, Kriz Jan, Goergen Helen, Tanner Antonia, Zijlstra Josée M, Greil Richard, Markova Jana, Sasse Stephanie, Fuchs Michael, Topp Max S, Soekler Martin, Mathas Stephan, Meissner Julia, Wilhelm Martin, Koch Peter, Lindemann Hans-Walter, Schalk Enrico, Semrau Robert
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Borchmann P, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause S, Mueller R, Fuchs M, Rank A, Greil R, Haverkamp H, Diehl V, Cerny T, Markova J, Ho A, Eich H, Mueller-Hermelink H, Kanz L, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011; 29:4234-42.
Oct 11, 2011Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Oct 11, 2011J Clin Oncol 2011; 29:4234-42
Borchmann Peter, Paulus Ursula, Smardova Lenka, Huber Christoph, Dörken Bernd, Nerl Christoph, Krause Stefan W, Mueller Rolf-Peter, Fuchs Michael, Rank Andreas, Greil Richard, Haverkamp Heinz, Diehl Volker, Cerny Thomas, Markova Jana, Ho Anthony D, Eich Hans-Theodor, Mueller-Hermelink Hans Konrad, Kanz Lothar, Engert Andreas